<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04875676</url>
  </required_header>
  <id_info>
    <org_study_id>VXA-NVV-105</org_study_id>
    <nct_id>NCT04875676</nct_id>
  </id_info>
  <brief_title>Immunogenicity &amp; Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines</brief_title>
  <acronym>VXA-NVV-105</acronym>
  <official_title>A Phase 1b, Open-label, Boost-optimization Study of an Adenoviral- Vector Based Oral Norovirus Vaccine (VXA-G1.1-NN) Expressing GI.1 VP1 Administered Orally to Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vaxart</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vaxart</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the immunogenicity of VXA-G1.1-NN with repeat-dose administration at Day 1 and&#xD;
      varying boost schedules (Week 4, 8 or 12 post initial dose) in healthy adults aged 18-55,&#xD;
      inclusive, and to assess the safety and tolerability of VXA- G1.1-NN with repeat-dose&#xD;
      administration at varying boost schedules (Week 4, 8 or 12) in healthy adults aged 18-55,&#xD;
      inclusive&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 30, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Actual">July 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Viral-capsid protein 1 (VP1)-specific antibody secreting cells (ASC) by enzyme-linked immunospot (ELISpot) assay</measure>
    <time_frame>Day 1 (Initial Vaccination) through Day 8 post boost (Second Vaccination)</time_frame>
    <description>Comparison of VPI specific immunoglobin A (IgA) ASC levels between the 3 study cohorts</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Norovirus G1.1 histo-blood group antigen (HBGA) blocking antibodies (BT50) Assay</measure>
    <time_frame>Day 1 (Initial Vaccination) through Day 29 post boost (Second Vaccination)</time_frame>
    <description>Comparison of GI.1 BT50 levels between the 3 study cohorts</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VP1 serum immunoglobin G (IgG) by ELISA</measure>
    <time_frame>Day 1 (Initial Vaccination) through Day 29 post boost (Second Vaccination)</time_frame>
    <description>Comparison of VPI specific immunoglobin A (IgA) ASC levels between the 3 study cohorts</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Solicited symptoms of Reactogenicity</measure>
    <time_frame>Day 1 (Vaccination) to Day 8 post each vaccination</time_frame>
    <description>Comparison of frequency, duration, and severity of solicited symptoms</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Unsolicited Adverse Events (AEs)</measure>
    <time_frame>Day 1 (Vaccine) through 28 days following boost (Second Vaccination)</time_frame>
    <description>Comparison of the frequency, duration, and severity of unsolicited AEs and serious AEs (SAEs) including AEs of Special Interest (AESIs) and new onsets of chronic illness (NOCIs)</description>
  </other_outcome>
  <other_outcome>
    <measure>Long-term Safety</measure>
    <time_frame>Day 1 (Vaccine) through 6 months following boost (Second Vaccination)</time_frame>
    <description>Frequency, duration, and severity of all SAEs, AESIs and NOCIs through 6 months after last vaccination.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Norovirus Infections</condition>
  <arm_group>
    <arm_group_label>Cohort 1 (4-week boost vaccination)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(4-week boost vaccination) 10 subjects will receive two doses of 1x10 log10 IU ± 0.5 log at Day 1 and Week 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (8-week boost vaccination)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(8-week boost vaccination) 10 subjects will receive two doses of 1x10 log10 IU± 0.5 log at Day 1 and Week 8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 (12-week boost vaccination)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(12-week boost vaccination) 10 subjects will receive two doses of 1x10 log10 IU± 0.5 log at Day 1 and Week 12</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VXA-G1.1-NN</intervention_name>
    <description>Norovirus GI.1 Norwalk VP1 Vaccine, Oral E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with double-stranded RNA Adjuvant</description>
    <arm_group_label>Cohort 1 (4-week boost vaccination)</arm_group_label>
    <arm_group_label>Cohort 2 (8-week boost vaccination)</arm_group_label>
    <arm_group_label>Cohort 3 (12-week boost vaccination)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  To be eligible for this study, participants must meet all the following:&#xD;
&#xD;
        Age&#xD;
&#xD;
          1. 18 to 55 years old inclusive at the time of signing the Informed Consent Form (ICF).&#xD;
&#xD;
             Type of Participants&#xD;
&#xD;
          2. General good health, without significant medical illness, based on medical history,&#xD;
             physical examination, vital signs, and clinical laboratories (CBC, chemistry, and&#xD;
             urinalysis) as determined by the investigator in consultation with the Research&#xD;
             Monitor and Sponsor&#xD;
&#xD;
          3. Body mass index (BMI) between 17 and 35 kg/m2 at screening&#xD;
&#xD;
          4. Available for all planned visits and phone calls, and willing to complete all&#xD;
             protocol- defined procedures and assessments (including ability and willingness to&#xD;
             swallow multiple small enteric-coated tablets per study dose).&#xD;
&#xD;
             Gender and Reproductive Considerations&#xD;
&#xD;
          5. Male or female participants Contraception use by men or women should be consistent&#xD;
             with local regulations regarding the methods of contraception for those participating&#xD;
             in clinical studies.&#xD;
&#xD;
             a. Female participants must provide a negative pregnancy test at each required visit&#xD;
             and fulfill one of the following criteria:&#xD;
&#xD;
               -  At least 1 year post-menopausal (defined as amenorrhea for ≥12 consecutive months&#xD;
                  prior to Screening without an alternative medical cause).&#xD;
&#xD;
               -  Women under 60 years will need to verify post-menopausal status via a&#xD;
                  follicle-stimulating hormone (FSH) test if another option to prevent potential&#xD;
                  pregnancy will not be utilized for 30 days prior to baseline vaccination and&#xD;
                  until 60 days after the last vaccination.&#xD;
&#xD;
               -  Surgically sterile&#xD;
&#xD;
               -  Use of oral, implantable, transdermal or injectable contraceptives for 30 days&#xD;
                  prior to initial vaccination and until 60 days after the last vaccination. The&#xD;
                  form of contraception must be approved by the Investigator&#xD;
&#xD;
               -  A reliable form of contraception must be approved by the Investigator (e.g.,&#xD;
                  double barrier method, Depo-Provera, intrauterine device, Norplant, oral&#xD;
                  contraceptives, contraceptive patches).&#xD;
&#xD;
               -  Not be sexually active (abstinent) or be in a relationship with partner who is&#xD;
                  sterile (must be discussed with site staff and documented).&#xD;
&#xD;
             Informed Consent&#xD;
&#xD;
          6. Capable of giving signed informed consent which includes compliance with the&#xD;
             requirements and restrictions listed in the ICF and in this protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The participants must be excluded from participating in the study if they meet any of&#xD;
             the following:&#xD;
&#xD;
        Medical Conditions&#xD;
&#xD;
          1. Presence of significant uncontrolled medical or psychiatric illness (acute or chronic)&#xD;
             including institution of new medical/surgical treatment or significant dose alteration&#xD;
             for uncontrolled symptoms or drug toxicity within 3 months of screening and&#xD;
             reconfirmed at baseline&#xD;
&#xD;
          2. Cancer, or received treatment for cancer, within past 3 years (excluding basal cell&#xD;
             carcinoma or squamous cell carcinoma)&#xD;
&#xD;
          3. Presence of immunosuppression or medical condition possibly associated with impaired&#xD;
             immune responsiveness, including diabetes mellitus 1 and 2&#xD;
&#xD;
          4. History of irritable bowel disease or other inflammatory digestive or gastrointestinal&#xD;
             condition that could affect the distribution/safety evaluation of an orally&#xD;
             administered vaccine targeting the mucosa of the small intestine.&#xD;
&#xD;
             Such conditions may include but are not limited to:&#xD;
&#xD;
               1. Esophageal Motility Disorder&#xD;
&#xD;
               2. Malignancy&#xD;
&#xD;
               3. Malabsorption&#xD;
&#xD;
               4. Pancreaticobiliary disorders&#xD;
&#xD;
               5. Irritable bowel syndrome&#xD;
&#xD;
               6. Inflammatory Bowel Disease&#xD;
&#xD;
               7. Surgical Resection&#xD;
&#xD;
               8. GERD&#xD;
&#xD;
               9. Hiatal Hernia&#xD;
&#xD;
              10. Peptic Ulcer (History of cholecystectomy is not exclusionary)&#xD;
&#xD;
          5. History of any form of angioedema&#xD;
&#xD;
          6. History of serious reactions to any vaccination such as anaphylaxis, respiratory&#xD;
             problems, hives or abdominal pain&#xD;
&#xD;
          7. Diagnosed bleeding disorder or significant bruising or bleeding difficulties that&#xD;
             could make blood draws problematic&#xD;
&#xD;
          8. Any condition that resulted in the absence or removal of the spleen&#xD;
&#xD;
          9. Acute disease within 72 hours prior to vaccination defined as the presence of a&#xD;
             moderate or severe illness (as determined by the Investigator through medical history&#xD;
             and physical exam). (Assessment may be repeated during screening period.)&#xD;
&#xD;
         10. Presence of a fever ≥ 38oC measured orally at baseline (Assessment may be repeated&#xD;
             during screening period)&#xD;
&#xD;
         11. Any significant hospitalization within the last year which in the opinion of the&#xD;
             Investigator or Sponsor could interfere with study participation.&#xD;
&#xD;
         12. Any other condition that in the clinical judgment of the investigator would jeopardize&#xD;
             the safety or rights of a participant taking in the study, would render the&#xD;
             participant unable to comply with the protocol or would interfere with the evaluation&#xD;
             of the study endpoints Diagnostic Assessments&#xD;
&#xD;
         13. Positive human immunodeficiency virus (HIV), Hepatitis B surface antigen (HBsAg) or&#xD;
             hepatitis C virus (HCV) tests at the screening visit&#xD;
&#xD;
         14. Positive urine drug screen for drugs of abuse at screening&#xD;
&#xD;
         15. Positive breath or urine alcohol test at screening and baseline Prior/Concurrent&#xD;
             Therapy&#xD;
&#xD;
         16. Receipt of a licensed vaccine within 14 days prior to baseline vaccination or planned&#xD;
             administration during the study active period (4 weeks post each study vaccination).&#xD;
&#xD;
         17. Use of antibiotics, proton pump inhibitors, H2 blockers or antacids within 7 days&#xD;
             prior to study drug administration or planned use during the active study period&#xD;
&#xD;
         18. Use of medications known to affect the immune function (e.g., systemic corticosteroids&#xD;
             and others) within 2 weeks before study drug administration or planned use during the&#xD;
             active study period&#xD;
&#xD;
         19. Daily use of nonsteroidal anti-inflammatory drugs within 7 days prior to study drug&#xD;
             administration or planned use during the active study period&#xD;
&#xD;
         20. Administration of any investigational vaccine, drug or device within 8 weeks preceding&#xD;
             study drug administration (Day 1), or planned use within the duration of the study&#xD;
             Other Exclusions&#xD;
&#xD;
         21. Donation or use of blood or blood products within 30 days prior to study drug&#xD;
             administration or planned donation during the active study period&#xD;
&#xD;
         22. History of drug, alcohol or chemical abuse within 1 year of screening&#xD;
&#xD;
         23. History of hypersensitivity or allergic reaction to any component of the&#xD;
             investigational vaccine, including but not limited to fish gelatin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helen Paguntalan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icon, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>WCCT Global, Inc.</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 19, 2021</study_first_submitted>
  <study_first_submitted_qc>April 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2021</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caliciviridae Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

